| 1 | Molecular Profiling of Low-Risk Papillary Thyroid Carcinoma (mPTC) on Active Surveillance | 4.1 | 9 | Citations (PDF) |
| 2 | Histologic parameters driving completion thyroidectomy for papillary thyroid carcinoma in a high-volume institution: A retrospective observational study | 1.7 | 1 | Citations (PDF) |
| 3 | The Usefulness of the International Grading System in the Management of Sporadic Medullary Thyroid Carcinoma | 4.4 | 3 | Citations (PDF) |
| 4 | Prophylactic central neck dissection in clinically node-negative papillary thyroid carcinoma: 10-year impact on surgical and oncologic outcomes | 1.8 | 4 | Citations (PDF) |
| 5 | Body Mass Index and Sporadic Medullary Thyroid Cancer: Insights from a Large Series | 3.8 | 0 | Citations (PDF) |
| 6 | Reproductive Factors, Sex Hormone Levels, and Differentiated Thyroid Cancer Risk: A Mendelian Randomization Study | 4.4 | 3 | Citations (PDF) |
| 7 | Genetic origin of multifocal sporadic medullary thyroid cancer and C-cell hyperplasia | 4.0 | 1 | Citations (PDF) |
| 8 | A Misleading Case of NTRK-Rearranged Papillary Thyroid Carcinoma | 3.4 | 4 | Citations (PDF) |
| 9 | Insights into highly selective RET inhibitors in medullary thyroid cancer | 1.0 | 1 | Citations (PDF) |
| 10 | Erectile Dysfunction in Patients Treated with Selpercatinib for
RET
-Altered Thyroid Cancer | 4.4 | 3 | Citations (PDF) |
| 11 | Insights into Ultrasound Features and Risk Stratification Systems in Pediatric Patients with Thyroid Nodules | 2.8 | 2 | Citations (PDF) |
| 12 | Minor role of TP53 and TERT promoter mutations in medullary thyroid carcinoma: report of new cases and revision of the literature | 2.5 | 2 | Citations (PDF) |
| 13 | Neoplasia follicolare della tiroide non invasiva con caratteristiche nucleari di tipo papillare (NIFTP): un’entità clinica di tutto rispetto | 0.0 | 0 | Citations (PDF) |
| 14 | Long-Term Outcome of Patients with Low-Risk Differentiated Thyroid Cancer Treated with Total Thyroidectomy Alone | 3.0 | 2 | Citations (PDF) |
| 15 | Pros and cons of an aggressive initial treatment with surgery and radioiodine treatment in minimally invasive follicular thyroid carcinoma | 1.6 | 3 | Citations (PDF) |
| 16 | Outcomes of the Tall-Cell Variant of Papillary Thyroid Carcinoma in Patients with Different Ages: A 17-Year Mono-Institutional Experience | 3.8 | 6 | Citations (PDF) |
| 17 | Clinical Evolution of Sporadic Medullary Thyroid Carcinoma With Biochemical Incomplete Response After Initial Treatment | 4.1 | 13 | Citations (PDF) |
| 18 | Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test | 2.8 | 10 | Citations (PDF) |
| 19 | Active surveillance in differentiated thyroid cancer: a strategy applicable to all treatment categories response | 3.9 | 2 | Citations (PDF) |
| 20 | Radio-iodine refractory thyroid cancer patients: a tailored follow-up based on clinicopathological features | 2.8 | 6 | Citations (PDF) |
| 21 | Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe | 2.6 | 9 | Citations (PDF) |
| 22 | Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing | 2.5 | 10 | Citations (PDF) |
| 23 | Cytological and Ultrasound Features of Thyroid Nodules Correlate With Histotypes and Variants of Thyroid Carcinoma | 4.1 | 9 | Citations (PDF) |
| 24 | Diagnosis and Management of Tropomyosin Receptor Kinase Fusion-Positive Thyroid Carcinomas | 14.4 | 17 | Citations (PDF) |
| 25 | NF1gene inactivation acts as a tumor driver inRET/RAS-negative medullary thyroid carcinomas | 4.0 | 11 | Citations (PDF) |
| 26 | Iperparatiroidismo nel contesto della MEN2A: dalla genetica alla gestione clinica | 0.0 | 0 | Citations (PDF) |
| 27 | Significance of Thyroglobulin Autoantibodies in Patients With Thyroid Cancer Treated With Lenvatinib | 0.3 | 1 | Citations (PDF) |
| 28 | Effect of Pregnancy and Menopause on Micropapillary Thyroid Carcinomas During Active Surveillance | 0.3 | 2 | Citations (PDF) |
| 29 | Ultrasound features and risk stratification system in NIFT-P and other follicular-patterned thyroid tumors | 4.0 | 16 | Citations (PDF) |
| 30 | Phase 3 Trial of Selpercatinib in Advanced
RET
-Mutant Medullary Thyroid Cancer | 34.6 | 144 | Citations (PDF) |
| 31 | BRAF K601E Mutation in Oncocytic Carcinoma of the Thyroid: A Case Report and Literature Review | 2.5 | 3 | Citations (PDF) |
| 32 | IgG4 serum levels in Graves’ orbitopathy | 2.8 | 2 | Citations (PDF) |
| 33 | Management of patients with extensive locally advanced thyroid cancer: results of multimodal treatments | 2.8 | 7 | Citations (PDF) |
| 34 | Effects of tyrosine kinase inhibitors on thyroid function and thyroid hormone metabolism | 13.7 | 33 | Citations (PDF) |
| 35 | Thyroidectomies in Italy: A Population-Based National Analysis from 2001 to 2018 | 4.4 | 15 | Citations (PDF) |
| 36 | Clinical-Pathological and Molecular Evaluation of 451 NIFTP Patients from a Single Referral Center | 3.8 | 13 | Citations (PDF) |
| 37 | Response to Letter to the Editor From Green and Gosmanov: “Tall Cell Percentage Alone in PTC Without Aggressive Features Should not Guide Patients’ Clinical Management” | 4.1 | 0 | Citations (PDF) |
| 38 | Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit | 3.4 | 34 | Citations (PDF) |
| 39 | Impact of energy-based devices in pediatric thyroid surgery | 2.0 | 1 | Citations (PDF) |
| 40 | Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine | 3.9 | 36 | Citations (PDF) |
| 41 | Nutrition in Advanced Thyroid Cancer Patients | 4.5 | 14 | Citations (PDF) |
| 42 | Clinical–Pathological Features and Treatment Outcome of Patients With Hobnail Variant Papillary Thyroid Carcinoma | 3.9 | 14 | Citations (PDF) |
| 43 | Core Needle Biopsy Can Early and Precisely Identify Large Thyroid Masses | 2.6 | 25 | Citations (PDF) |
| 44 | A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg Per Day Compared with the Cabozantinib Capsule at 140 mg Per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer | 4.4 | 15 | Citations (PDF) |
| 45 | Pre- and Post-operative Circulating Tumoral DNA in Patients With Medullary Thyroid Carcinoma | 4.1 | 15 | Citations (PDF) |
| 46 | Predictive Biomarkers in Thyroid Cancer | 2.6 | 13 | Citations (PDF) |
| 47 | Somatic RET Indels in Sporadic Medullary Thyroid Cancer: Prevalence and Response to Selpercatinib | 4.1 | 34 | Citations (PDF) |
| 48 | Limited Accuracy of Pan-Trk Immunohistochemistry Screening for NTRK Rearrangements in Follicular-Derived Thyroid Carcinoma | 4.4 | 10 | Citations (PDF) |
| 49 | Libretto-531: A Phase III Study of Selpercatinib in Multikinase Inhibitor-Naïve
RET
-Mutant Medullary Thyroid Cancer | 2.3 | 29 | Citations (PDF) |
| 50 | Understanding the effect of obesity on papillary thyroid cancer: is there a need for tailored diagnostic and therapeutic management? | 2.9 | 5 | Citations (PDF) |
| 51 | Re: “Symptomatic Biliary Disorders During Lenvatinib Treatment for Thyroid Cancer: An Underestimated Problem” by Nervo
et al. | 4.4 | 2 | Citations (PDF) |
| 52 | First report of benign track seeding after robot-assisted transaxillary thyroid surgery | 1.5 | 9 | Citations (PDF) |
| 53 | Ca19.9 Positivity and Doubling Time Are Prognostic Factors of Mortality in Patients with Advanced Medullary Thyroid Cancer with No Evidence of Structural Disease Progression According to Response Evaluation Criteria in Solid Tumors | 4.4 | 17 | Citations (PDF) |
| 54 | Pro64His (rs4644) Polymorphism Within Galectin-3 Is a Risk Factor of Differentiated Thyroid Carcinoma and Affects the Transcriptome of Thyrocytes Engineered via CRISPR/Cas9 System | 4.4 | 5 | Citations (PDF) |
| 55 | Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer | 4.4 | 34 | Citations (PDF) |
| 56 | Multiethnic genome‐wide association study of differentiated thyroid cancer in the
EPITHYR
consortium | 4.3 | 22 | Citations (PDF) |
| 57 | A Narrative Review of Genetic Alterations in Primary Thyroid Epithelial Cancer | 4.4 | 79 | Citations (PDF) |
| 58 | Thyroid cancer and COVID-19: experience at one single thyroid disease referral center | 2.5 | 12 | Citations (PDF) |
| 59 | Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer | 2.8 | 20 | Citations (PDF) |
| 60 | Thyroid Cancers: From Surgery to Current and Future Systemic Therapies through Their Molecular Identities | 4.4 | 61 | Citations (PDF) |
| 61 | [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival | 4.1 | 19 | Citations (PDF) |
| 62 | Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade | 0.3 | 4 | Citations (PDF) |
| 63 | Tall cell percentage alone in PTC without aggressive features should not guide patients’ clinical management | 4.1 | 21 | Citations (PDF) |
| 64 | Poorly Differentiated and Anaplastic Thyroid Cancer: Insights into Genomics, Microenvironment and New Drugs | 3.8 | 24 | Citations (PDF) |
| 65 | Whole Tumor Capsule Is Prognostic of Very Good Outcome in the Classical Variant of Papillary Thyroid Cancer | 4.1 | 19 | Citations (PDF) |
| 66 | Molecular Alterations in Relation to Histopathological Characteristics in a Large Series of Pediatric Papillary Thyroid Carcinoma from a Single Institution | 3.8 | 18 | Citations (PDF) |
| 67 | Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates | 2.8 | 16 | Citations (PDF) |
| 68 | Clinical pharmacology and drug-drug interactions of lenvatinib in thyroid cancer | 5.0 | 10 | Citations (PDF) |
| 69 | BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer | 4.1 | 57 | Citations (PDF) |
| 70 | Assessing mPTC Progression during Active Surveillance: Volume or Diameter Increase? | 2.5 | 15 | Citations (PDF) |
| 71 | Impact of Advanced Age on the Clinical Presentation and Outcome of Sporadic Medullary Thyroid Carcinoma | 3.8 | 22 | Citations (PDF) |
| 72 | Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma | 4.2 | 6 | Citations (PDF) |
| 73 | RET Copy Number Alteration in Medullary Thyroid Cancer Is a Rare Event Correlated with RET Somatic Mutations and High Allelic Frequency | 2.5 | 3 | Citations (PDF) |
| 74 | Active Surveillance in RET Gene Carriers Belonging to Families with Multiple Endocrine Neoplasia | 3.8 | 8 | Citations (PDF) |
| 75 | La gestione multidisciplinare delle metastasi ossee nel carcinoma tiroideo | 0.0 | 0 | Citations (PDF) |
| 76 | Delayed 131-I First Treatment After Surgery has No Impact on the Median Term Outcome of Patients with Intermediate Risk Differentiated Thyroid Cancer | 3.3 | 19 | Citations (PDF) |
| 77 | Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center | 4.1 | 137 | Citations (PDF) |
| 78 | BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma | 4.9 | 49 | Citations (PDF) |
| 79 | Potential Impact of BMI on the Aggressiveness of Presentation and Clinical Outcome of Differentiated Thyroid Cancer | 4.1 | 34 | Citations (PDF) |
| 80 | Qualità della vita nei pazienti con microcarcinoma papillare della tiroide in funzione del trattamento: tiroidectomia totale con o senza terapia radiometabolica ablativa | 0.0 | 0 | Citations (PDF) |
| 81 | Obesity as a risk factor for thyroid cancer | 2.3 | 57 | Citations (PDF) |
| 82 | A New MEN2 Syndrome with Clinical Features of Both MEN2A and MEN2B Associated with a New
RET
Germline Deletion | 0.5 | 7 | Citations (PDF) |
| 83 | Response to Letter to the Editor: “Active Surveillance in Papillary Thyroid Microcarcinomas is Feasible and Safe: Experience at a Single Italian Center” | 4.1 | 0 | Citations (PDF) |
| 84 | Thyroglobulin Changes are Highly Dependent on TSH in Low-risk DTC Patients not Treated with Radioiodine | 4.1 | 12 | Citations (PDF) |
| 85 | Outcome of classical (CVPTC) and follicular (FVPTC) variants of papillary thyroid cancer: 15 years of follow-up | 2.5 | 12 | Citations (PDF) |
| 86 | Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey | 3.9 | 13 | Citations (PDF) |
| 87 | Polymorphisms Within the
RET
Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma | 4.4 | 6 | Citations (PDF) |
| 88 | Proteinuria is a late-onset adverse event in patients treated with cabozantinib | 2.8 | 20 | Citations (PDF) |
| 89 | Using The Cancer Genome Atlas data to refine the 8th edition of the American Joint Committee on Cancer staging for papillary thyroid carcinoma | 2.5 | 2 | Citations (PDF) |
| 90 | Nonthyroidal second primary malignancies in differentiated thyroid cancer patients: Is the incidence increased comparing to the general population and could it be a radioiodine therapy consequence? | 4.3 | 21 | Citations (PDF) |
| 91 | Role of Prophylactic Central Compartment Lymph Node Dissection on the Outcome Of Patients With Papillary Thyroid Carcinoma and Synchronous Ipsilateral Cervical Lymph Node Metastases | 3.3 | 17 | Citations (PDF) |
| 92 | MON-537 Primary Adrenal Insufficiency During Tyrosine Kinase Inhibitors Treatment in Advanced Thyroid Cancer Patients | 0.3 | 0 | Citations (PDF) |
| 93 | MON-486 Polygenic Susceptibility to Papillary Thyroid Cancer in Italian Subjects | 0.3 | 0 | Citations (PDF) |
| 94 | Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy | 4.9 | 85 | Citations (PDF) |
| 95 | Differential expression of RET isoforms in normal thyroid tissues, papillary and medullary thyroid carcinomas | 2.5 | 4 | Citations (PDF) |
| 96 | Epidemiology of Simultaneous Medullary and Papillary Thyroid Carcinomas (MTC/PTC): An Italian Multicenter Study | 3.8 | 42 | Citations (PDF) |
| 97 | Twenty-Five Years Experience on RET Genetic Screening on Hereditary MTC: An Update on The Prevalence of Germline RET Mutations | 2.5 | 79 | Citations (PDF) |
| 98 | Genetic Landscape of Somatic Mutations in a Large Cohort of Sporadic Medullary Thyroid Carcinomas Studied by Next-Generation Targeted Sequencing | 3.6 | 195 | Citations (PDF) |
| 99 | Lenvatinib Administered via Nasogastric Tube in Poorly Differentiated Thyroid Cancer | 0.5 | 5 | Citations (PDF) |
| 100 | Fifty Years After the First Description, MEN 2B Syndrome Diagnosis Is Still Late: Descriptions of Two Recent Cases | 4.1 | 21 | Citations (PDF) |
| 101 | Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma | 0.3 | 18 | Citations (PDF) |
| 102 | The Molecular Signature More Than the Site of Localization Defines the Origin of the Malignancy | 2.6 | 4 | Citations (PDF) |
| 103 | Management of Medullary Thyroid Cancer | 3.5 | 91 | Citations (PDF) |
| 104 | European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium | 4.4 | 154 | Citations (PDF) |
| 105 | Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study | 21.8 | 128 | Citations (PDF) |
| 106 | Less than 2% of the Low- and Intermediate-Risk Differentiated Thyroid Cancers Show Distant Metastases at Post-Ablation Whole-Body Scan | 0.9 | 13 | Citations (PDF) |
| 107 | mRNA and miRNA expression profiling of follicular variant of papillary thyroid carcinoma with and without distant metastases | 3.4 | 8 | Citations (PDF) |
| 108 | Features and outcome of differentiated thyroid carcinoma associated with Graves’ disease: results of a large, retrospective, multicenter study | 2.8 | 25 | Citations (PDF) |
| 109 | A patient with MEN1 and end‑stage chronic kidney disease due to Alport syndrome: Decision making on the eligibility of transplantation | 1.2 | 0 | Citations (PDF) |
| 110 | mRECIST criteria to assess recurrent thyroid carcinoma treatment response after radiofrequency ablation: a prospective study | 2.8 | 19 | Citations (PDF) |
| 111 | BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment | 4.6 | 69 | Citations (PDF) |
| 112 | Analysis of circulating tumor DNA does not improve the clinical management of patients with locally advanced and metastatic papillary thyroid carcinoma | 2.0 | 34 | Citations (PDF) |
| 113 | Lung Recurrence of Papillary Thyroid Cancer Diagnosed With Antithyroglobulin Antibodies After 10 Years From Initial Treatment | 3.9 | 5 | Citations (PDF) |
| 114 | Clinical, pathological and genetic features of anaplastic and poorly differentiated thyroid cancer: A single institute experience | 1.9 | 31 | Citations (PDF) |
| 115 | Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without
131
I Ablation | 4.4 | 40 | Citations (PDF) |
| 116 | SP134PROTEINURIA IS A LATE ONSET ADVERSE EVENT IN PATIENTS TREATED WITH CABOZANTINIB: A SINGLE CENTER EXPERIENCE | 0.8 | 1 | Citations (PDF) |
| 117 | The polymorphism rs2480258 within CYP2E1 is associated with different rates of acrylamide metabolism in vivo in humans | 5.8 | 9 | Citations (PDF) |
| 118 | Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies | 2.8 | 199 | Citations (PDF) |
| 119 | Patients with Indeterminate Thyroid Nodules at Cytology and Cancer at Histology Have a More Favorable Outcome Compared with Patients with Suspicious or Malignant Cytology | 4.4 | 7 | Citations (PDF) |
| 120 | Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid | 4.9 | 72 | Citations (PDF) |
| 121 | Clinical impact of molecular techniques for the presurgical diagnosis of differentiated thyroid cancer diagnosis | 2.9 | 0 | Citations (PDF) |
| 122 | Response to Letter: “Postoperative Thyroglobulin and Neck Ultrasound in the Risk Restratification and Decision to Perform 131I Ablation” | 4.1 | 2 | Citations (PDF) |
| 123 | Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life | 5.1 | 29 | Citations (PDF) |
| 124 | The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer | 4.1 | 97 | Citations (PDF) |
| 125 | Targeted Therapy in Thyroid Cancer: State of the Art | 1.6 | 128 | Citations (PDF) |
| 126 | Incidental occurrence of metastatic medullary thyroid carcinoma in a patient with multiple endocrine neoplasia type 1 carrying germline MEN1 and somatic RET mutations | 1.5 | 5 | Citations (PDF) |
| 127 | Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma | 10.0 | 213 | Citations (PDF) |
| 128 | Comunicare con la persona con cancro della tiroide in progressione | 0.0 | 1 | Citations (PDF) |
| 129 | Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies | 32.0 | 424 | Citations (PDF) |
| 130 | KIF5B/RET Rearrangement in a Carcinoma of the Thyroid Gland: A Case Report of a Fatal Disease | 4.1 | 2 | Citations (PDF) |
| 131 | Role of YAP-1 in Thyroid Tumor Progression and Outcome | 1.0 | 9 | Citations (PDF) |
| 132 | Identification of Two Distinct Molecular Subtypes of Non-Invasive Follicular Neoplasm with Papillary-Like Nuclear Features by Digital RNA Counting | 4.4 | 30 | Citations (PDF) |
| 133 | Use of low-dose radioiodine ablation for Graves’ orbitopathy: results of a pilot, perspective study in a small series of patients | 2.8 | 5 | Citations (PDF) |
| 134 | Inherited variants in genes somatically mutated in thyroid cancer | 2.3 | 6 | Citations (PDF) |
| 135 | Lenvatinib and other tyrosine kinase inhibitors for the treatment of radioiodine refractory, advanced, and progressive thyroid cancer | 2.7 | 44 | Citations (PDF) |
| 136 | New insights in the molecular signature of advanced medullary thyroid cancer: evidence of a bad outcome of cases with double RET mutations | 3.8 | 81 | Citations (PDF) |
| 137 | Reply to the Letter to the Editor by Sollini M et al. | 2.8 | 2 | Citations (PDF) |
| 138 | Polymorphisms within base and nucleotide excision repair pathways and risk of differentiated thyroid carcinoma | 2.5 | 8 | Citations (PDF) |
| 139 | Runs of homozygosity and inbreeding in thyroid cancer | 2.9 | 20 | Citations (PDF) |
| 140 | Correlative analyses of
RET
and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer | 4.0 | 90 | Citations (PDF) |
| 141 | Papillary Thyroid Carcinoma With Rare Exon 15 BRAF Mutation Has Indolent Behavior: A Single-Institution Experience | 4.1 | 52 | Citations (PDF) |
| 142 | Effect of an Outreach Programme on Vandetanib Safety in Medullary Thyroid Cancer | 0.9 | 13 | Citations (PDF) |
| 143 | Association between CYP2E1 polymorphisms and risk of differentiated thyroid carcinoma | 5.8 | 9 | Citations (PDF) |
| 144 | Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants | 4.1 | 195 | Citations (PDF) |
| 145 | A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma | 32.0 | 325 | Citations (PDF) |
| 146 | A Comprehensive Meta-analysis of Case–Control Association Studies to Evaluate Polymorphisms Associated with the Risk of Differentiated Thyroid Carcinoma | 1.1 | 26 | Citations (PDF) |
| 147 | A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer | 6.8 | 220 | Citations (PDF) |
| 148 | Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland | 2.8 | 38 | Citations (PDF) |
| 149 | Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age | 1.7 | 9 | Citations (PDF) |
| 150 | A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment | 4.0 | 175 | Citations (PDF) |
| 151 | Novel genetic variants in differentiated thyroid cancer and assessment of the cumulative risk | 3.4 | 24 | Citations (PDF) |
| 152 | Cabozantinib: an orphan drug for thyroid cancer | 1.0 | 2 | Citations (PDF) |
| 153 | Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group | 4.1 | 12 | Citations (PDF) |
| 154 | Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer | 34.6 | 1,845 | Citations (PDF) |
| 155 | Prophylactic Central Compartment Lymph Node Dissection in Papillary Thyroid Carcinoma: Clinical Implications Derived From the First Prospective Randomized Controlled Single Institution Study | 4.1 | 279 | Citations (PDF) |
| 156 | Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma | 4.4 | 2,168 | Citations (PDF) |
| 157 | Effects of radioiodine treatment for differentiated thyroid cancer on testis function | 2.3 | 20 | Citations (PDF) |
| 158 | Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer? | 2.3 | 47 | Citations (PDF) |
| 159 | Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology | 2.8 | 32 | Citations (PDF) |
| 160 | Thyroid carcinoma in thyrotoxic patients treated by surgery | 2.8 | 36 | Citations (PDF) |
| 161 | Expression of calcitonin gene-related peptide in medullary thyroid cancer | 2.8 | 11 | Citations (PDF) |
| 162 | Lack of evidence supporting the presence of mRNA for the thyrotropin receptor in extra-ocular muscle | 2.8 | 3 | Citations (PDF) |
| 163 | Measurement of cAMP accumulation in Chinese hamster ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay for human thyrotropin | 2.8 | 17 | Citations (PDF) |
| 164 | Muscle autoantigens in thyroid associated ophthalmopathy: The limits of molecular genetics | 2.8 | 2 | Citations (PDF) |
| 165 | Post-surgical follow-up of differentiated thyroid cancer | 2.8 | 8 | Citations (PDF) |
| 166 | Transfection with the cDNA of the human thyrotropin receptor of a poorly differentiated rat thyroid cell line (FRT) | 2.8 | 2 | Citations (PDF) |
| 167 | RET proto-oncogene mutations in thyroid carcinomas: Clinical relevance | 2.8 | 15 | Citations (PDF) |
| 168 | Post-surgical ablation of thyroid residues with radioiodine in Ukrainian children and adolescents affected by post-Chernobyl differentiated thyroid cancer | 2.8 | 3 | Citations (PDF) |
| 169 | Diagnosi genetica del carcinoma midollare della tiroide: implicazioni diagnostiche e terapeutiche | 0.0 | 0 | Citations (PDF) |
| 170 | Location of functioning metastases from differentiated thyroid carcinoma by simultaneous double isotope acquisition of I-131 whole body scan and bone scan | 2.8 | 6 | Citations (PDF) |
| 171 | Video assisted prophylactic thyroidectomy and central compartment nodes clearance in two RET gene mutation adult carriers | 2.8 | 10 | Citations (PDF) |
| 172 | Failure to use measurement of megalin secretory components complexed with serum thyroglobulin as a tool to identify metastases after surgery in papillary thyroid cancer | 2.8 | 1 | Citations (PDF) |
| 173 | Interventional bronchoscopy in the treatment of tracheal obstruction secondary to advanced thyroid cancer | 2.8 | 23 | Citations (PDF) |
| 174 | Retinoic acid receptor β2 re-expression and growth inhibition in thyroid carcinoma cell lines after 5-aza-2′-deoxycytidine treatment | 2.8 | 16 | Citations (PDF) |
| 175 | Correlazione genotipo-fenotipo nelle MEN 2: stato dell’arte dopo 15 anni di conoscenze | 0.0 | 0 | Citations (PDF) |
| 176 | Nuove indicazioni all’impiego del TSH umano ricombinante (rhTSH) e basse attività di 131I nella radioablazione del residuo tiroideo post-chirurgico | 0.0 | 0 | Citations (PDF) |
| 177 | Novel Genome-Wide Association Study–Based Candidate Loci for Differentiated Thyroid Cancer Risk | 4.1 | 44 | Citations (PDF) |
| 178 | Obesity and the Risk of Papillary Thyroid Cancer: A Pooled Analysis of Three Case–Control Studies | 4.4 | 108 | Citations (PDF) |
| 179 | FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment | 4.4 | 27 | Citations (PDF) |
| 180 | Detection of metastases from differentiated thyroid cancer by different imaging techniques (neck ultrasound, computed tomography and [18F]-FDG positron emission tomography) in patients with negative post-therapeutic 131I whole-body scan and detectable serum thyroglobulin levels | 2.8 | 9 | Citations (PDF) |
| 181 | Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma | 4.4 | 140 | Citations (PDF) |
| 182 | Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial | 62.3 | 1,501 | Citations (PDF) |
| 183 | Molecular Profiles of Papillary Thyroid Tumors Have Been Changing in the Last Decades: How Could We Explain It? | 4.1 | 11 | Citations (PDF) |
| 184 | Il carcinoma tiroideo: nuove prospettive terapeutiche | 0.0 | 0 | Citations (PDF) |
| 185 | How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level | 3.5 | 16 | Citations (PDF) |
| 186 | Incidental versus clinically evident thyroid cancer: A 5‐year follow‐up study | 2.0 | 7 | Citations (PDF) |
| 187 | Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association | 1.6 | 30 | Citations (PDF) |
| 188 | Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer | 16.6 | 859 | Citations (PDF) |
| 189 | Medullary thyroid carcinoma (MTC) and RET proto-oncogene: Mutation spectrum in the familial cases and a meta-analysis of studies on the sporadic form | 4.1 | 81 | Citations (PDF) |
| 190 | Genome-Wide Association Study on Differentiated Thyroid Cancer | 4.1 | 122 | Citations (PDF) |
| 191 | Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement | 4.4 | 165 | Citations (PDF) |
| 192 | Evidence of a Low Prevalence of
RAS
Mutations in a Large Medullary Thyroid Cancer Series | 4.4 | 166 | Citations (PDF) |
| 193 | Medullary Thyroid Cancer Secreting Carbohydrate Antigen 19-9 (Ca 19-9): A Fatal Case Report | 4.1 | 26 | Citations (PDF) |
| 194 | TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations | 4.3 | 30 | Citations (PDF) |
| 195 | Patients With Differentiated Thyroid Cancer Who Underwent Radioiodine Thyroid Remnant Ablation With Low-Activity 131I After Either Recombinant Human TSH or Thyroid Hormone Therapy Withdrawal Showed the Same Outcome After a 10-Year Follow-up | 4.1 | 62 | Citations (PDF) |
| 196 | Cabozantinib (XL184) for the Treatment of Locally Advanced or Metastatic Progressive Medullary Thyroid Cancer | 2.3 | 80 | Citations (PDF) |
| 197 | TheBRAFV600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study | 4.1 | 231 | Citations (PDF) |
| 198 | Modifications in the Papillary Thyroid Cancer Gene Profile Over the Last 15 Years | 4.1 | 86 | Citations (PDF) |
| 199 | The Timing of Total Thyroidectomy in
RET
Gene Mutation Carriers Could Be Personalized and Safely Planned on the Basis of Serum Calcitonin: 18 Years Experience at One Single Center | 4.1 | 133 | Citations (PDF) |
| 200 | Advances in the follow-up of differentiated or medullary thyroid cancer | 32.0 | 81 | Citations (PDF) |
| 201 | Chromosome 10 and RET gene copy number alterations in hereditary and sporadic Medullary Thyroid Carcinoma | 3.4 | 22 | Citations (PDF) |
| 202 | Low Prevalence of the Somatic M918T
RET
Mutation in Micro-Medullary Thyroid Cancer | 4.4 | 68 | Citations (PDF) |
| 203 | Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer | 1.8 | 47 | Citations (PDF) |
| 204 | Genetic and Clinical Features of Multiple Endocrine Neoplasia Types 1 and 2 | 3.9 | 89 | Citations (PDF) |
| 205 | RET/PTC Translocations and Clinico-Pathological Features in Human Papillary Thyroid Carcinoma | 3.9 | 145 | Citations (PDF) |
| 206 | Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line | 3.4 | 16 | Citations (PDF) |
| 207 | RET point mutations in Thyroid Carcinoma | 0.2 | 0 | Citations (PDF) |
| 208 | RET genetic screening of sporadic medullary thyroid cancer (MTC) allows the preclinical diagnosis of unsuspected gene carriers and the identification of a relevant percentage of hidden familial MTC (FMTC) | 2.3 | 114 | Citations (PDF) |
| 209 | Evidences that the polymorphism Pro‐282‐Ala within the tumor suppressor gene WWOX is a new risk factor for differentiated thyroid carcinoma | 4.3 | 29 | Citations (PDF) |
| 210 | Higher Intratumoral Expression of CD1a, Tryptase, and CD68 in a Follicular Variant of Papillary Thyroid Carcinoma Compared to Adenomas: Correlation with Clinical and Pathological Parameters | 4.4 | 40 | Citations (PDF) |
| 211 | Correlation between the
BRAF
V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases | 4.1 | 175 | Citations (PDF) |
| 212 | Are the Clinical and Pathological Features of Differentiated Thyroid Carcinoma Really Changed over the Last 35 Years? Study on 4187 Patients from a Single Italian Institution to Answer this Question | 4.1 | 210 | Citations (PDF) |
| 213 | Role of RET codonic mutations in the surgical management of medullary thyroid carcinoma in pediatric age multiple endocrine neoplasm type 2 syndromes | 2.0 | 19 | Citations (PDF) |
| 214 | Follow-Up of Low-Risk Differentiated Thyroid Cancer Patients Who Underwent Radioiodine Ablation of Postsurgical Thyroid Remnants after Either Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal | 4.1 | 81 | Citations (PDF) |
| 215 | A Morpho-Molecular Diagnosis of Papillary Thyroid Carcinoma: BRAF V600E Detection as an Important Tool in Preoperative Evaluation of Fine-Needle Aspirates | 4.4 | 81 | Citations (PDF) |
| 216 | Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2′-deoxycytidine and retinoic acid | 3.4 | 42 | Citations (PDF) |
| 217 | Surgical Treatment of Low- and Intermediate-Risk Papillary Thyroid Cancer with Minimally Invasive Video-Assisted Thyroidectomy | 4.1 | 96 | Citations (PDF) |
| 218 | T cell responses to orbital antigens in thyroid-associated ophthalmopathy | 3.4 | 4 | Citations (PDF) |
| 219 | Routine serum calcitonin measurement in the evaluation of thyroid nodules | 5.1 | 83 | Citations (PDF) |
| 220 | Expression analysis of facilitative glucose transporters (GLUTs) in human thyroid carcinoma cell lines and primary tumors | 3.4 | 55 | Citations (PDF) |
| 221 | Prognostic Significance of Somatic RET Oncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study | 4.1 | 514 | Citations (PDF) |
| 222 | BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer | 3.5 | 145 | Citations (PDF) |
| 223 | Thyroid Autoantibodies and Thyroid Function in Subjects Exposed to Chernobyl Fallout during Childhood: Evidence for a Transient Radiation-Induced Elevation of Serum Thyroid Antibodies without an Increase in Thyroid Autoimmune Disease | 4.1 | 52 | Citations (PDF) |
| 224 | BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study | 4.1 | 502 | Citations (PDF) |
| 225 | Combined clinical, thyroid ultrasound and cytological features help to predict thyroid malignancy in follicular and Hrthle cell thyroid lesions: results from a series of 505 consecutive patients | 2.3 | 151 | Citations (PDF) |
| 226 | RET Genetic Screening in Patients with Medullary Thyroid Cancer and Their Relatives: Experience with 807 Individuals at One Center | 4.1 | 251 | Citations (PDF) |
| 227 | Clinically unpredictable prognostic factors in the outcome of medullary thyroid cancer | 3.5 | 49 | Citations (PDF) |
| 228 | Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity | 2.3 | 18 | Citations (PDF) |
| 229 | Lymphocyte and Immature Dendritic Cell Infiltrates in Differentiated, Poorly Differentiated, and Undifferentiated Thyroid Carcinoma | 4.4 | 82 | Citations (PDF) |
| 230 | Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma | 4.4 | 65 | Citations (PDF) |
| 231 | Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular | 1.0 | 0 | Citations (PDF) |
| 232 | The Heterogeneous Distribution of BRAF Mutation Supports the Independent Clonal Origin of Distinct Tumor Foci in Multifocal Papillary Thyroid Carcinoma | 4.1 | 100 | Citations (PDF) |
| 233 | Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma | 4.1 | 384 | Citations (PDF) |
| 234 | Radioiodine Ablation of Thyroid Remnants after Preparation with Recombinant Human Thyrotropin in Differentiated Thyroid Carcinoma: Results of an International, Randomized, Controlled Study | 4.1 | 420 | Citations (PDF) |
| 235 | Treatment with Drugs Able to Reduce Iodine Efflux Significantly Increases the Intracellular Retention Time in Thyroid Cancer Cells Stably Transfected with Sodium Iodide Symporter Complementary Deoxyribonucleic Acid | 4.1 | 42 | Citations (PDF) |
| 236 | Video-assisted central compartment lymphadenectomy in a patient with a positive RET oncogene: initial experience | 2.3 | 56 | Citations (PDF) |
| 237 | All-Trans-Retinoic Acid Treatment Inhibits the Growth of Retinoic Acid Receptor β Messenger Ribonucleic Acid Expressing Thyroid Cancer Cell Lines but Does Not Reinduce the Expression of Thyroid-Specific Genes | 4.1 | 43 | Citations (PDF) |
| 238 | Influence of Human Body Composition on Serum Peak Thyrotropin (TSH) after Recombinant Human TSH Administration in Patients with Differentiated Thyroid Carcinoma | 4.1 | 26 | Citations (PDF) |
| 239 | RET/PTC3 Rearrangement and Thyroid Differentiation Gene Analysis in a Struma Ovarii Fortuitously Revealed by Elevated Serum Thyroglobulin Concentration | 4.4 | 25 | Citations (PDF) |
| 240 | Lean Body Mass Is a Major Determinant of Levothyroxine Dosage in the Treatment of Thyroid Diseases | 4.1 | 219 | Citations (PDF) |
| 241 | A New Germline RET Mutation Apparently Devoid of Transforming Activity Serendipitously Discovered in a Patient with Atrophic Autoimmune Thyroiditis and Primary Ovarian Failure | 4.1 | 18 | Citations (PDF) |
| 242 | Medullary and Papillary Tumors Are Frequently Associated in the Same Thyroid Gland without Evidence of Reciprocal Influence in Their Biologic Behavior | 4.4 | 72 | Citations (PDF) |
| 243 | RET Exon 11 (G691S) Polymorphism Is Significantly More Frequent in Sporadic Medullary Thyroid Carcinoma Than in the General Population | 4.1 | 113 | Citations (PDF) |
| 244 | Low Specificity of Blood Thyroglobulin Messenger Ribonucleic Acid Assay Prevents Its Use in the Follow-Up of Differentiated Thyroid Cancer Patients | 4.1 | 56 | Citations (PDF) |
| 245 | Impact of Routine Measurement of Serum Calcitonin on the Diagnosis and Outcome of Medullary Thyroid Cancer: Experience in 10,864 Patients with Nodular Thyroid Disorders | 4.1 | 495 | Citations (PDF) |
| 246 | Initial therapy of differentiated thyroid carcinoma: an update on surgery and radioiodine | 0.3 | 0 | Citations (PDF) |
| 247 | BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid Carcinomas | 4.1 | 262 | Citations (PDF) |
| 248 | Identification of a Novel Point Mutation in the RET Gene (Ala883Thr), Which Is Associated with Medullary Thyroid Carcinoma Phenotype Only in Homozygous Condition | 4.1 | 67 | Citations (PDF) |
| 249 | Authors’ Response: Should Serum Calcitonin Be Routinely Measured in Patients with Thyroid Nodules—Will the Law Answer before Endocrinologists Do? | 4.1 | 0 | Citations (PDF) |
| 250 | Congenital hypothyroidism due to a new deletion in the sodium/iodide symporter protein | 2.3 | 24 | Citations (PDF) |
| 251 | Recombinant Human Thyrotropin-Stimulated Serum Thyroglobulin Combined with Neck Ultrasonography Has the Highest Sensitivity in Monitoring Differentiated Thyroid Carcinoma | 4.1 | 395 | Citations (PDF) |
| 252 | Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcription-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens | 4.4 | 52 | Citations (PDF) |
| 253 | Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1 | 4.1 | 62 | Citations (PDF) |
| 254 | Simian Virus 40-Like Sequences from Early and Late Regions in Human Thyroid Tumors of Different Histotypes | 4.1 | 30 | Citations (PDF) |
| 255 | Cytotoxic Effects of Carboplatinum and Epirubicin in the Setting of an Elevated Serum Thyrotropin for Advanced Poorly Differentiated Thyroid Cancer | 4.1 | 92 | Citations (PDF) |
| 256 | Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment | 4.1 | 267 | Citations (PDF) |
| 257 | Ablation of Thyroid Residues with 30 mCi 131I: A Comparison in Thyroid Cancer Patients Prepared with Recombinant Human TSH or Thyroid Hormone Withdrawal | 4.1 | 173 | Citations (PDF) |
| 258 | Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma | 3.4 | 105 | Citations (PDF) |
| 259 | Minimally invasive video-assisted thyroidectomy for papillary carcinoma: A prospective study of its completeness | 1.8 | 204 | Citations (PDF) |
| 260 | Thyroid diseases around Chernobyl: from autoimmune diseases to malignant tumors | 0.2 | 2 | Citations (PDF) |
| 261 | Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying theRET/PTC1 rearrangement | 4.3 | 42 | Citations (PDF) |
| 262 | Diagnostic 131-Iodine Whole-Body Scan May Be Avoided in Thyroid Cancer Patients Who Have Undetectable Stimulated Serum Tg Levels After Initial Treatment | 4.1 | 67 | Citations (PDF) |
| 263 | RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults1 | 4.1 | 237 | Citations (PDF) |
| 264 | Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated Patients | 4.1 | 234 | Citations (PDF) |
| 265 | Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma | 4.1 | 169 | Citations (PDF) |
| 266 | Contralateral Papillary Thyroid Cancer is Frequent at Completion Thyroidectomy with No Difference in Low- and High-Risk Patients | 4.4 | 143 | Citations (PDF) |
| 267 | Prediction of Disease Status by Recombinant Human TSH-Stimulated Serum Tg in the Postsurgical Follow-Up of Differentiated Thyroid Carcinoma | 4.1 | 62 | Citations (PDF) |
| 268 | RET/PTC Rearrangements in Thyroid Nodules: Studies in Irradiated and Not Irradiated, Malignant and Benign Thyroid Lesions in Children and Adults | 4.1 | 187 | Citations (PDF) |
| 269 | Outcome of Differentiated Thyroid Cancer with Detectable Serum Tg and Negative Diagnostic 131I Whole Body Scan: Comparison of Patients Treated with High 131I Activities Versus Untreated Patients | 4.1 | 77 | Citations (PDF) |
| 270 | New breakpoints in both the H4 and RET genes create a variant of PTC-1 in a post-Chernobyl papillary thyroid carcinoma | 2.3 | 17 | Citations (PDF) |
| 271 | N-ras Mutation in Poorly Differentiated Thyroid Carcinomas: Correlation with Bone Metastases and Inverse Correlation to Thyroglobulin Expression | 4.4 | 160 | Citations (PDF) |
| 272 | Conditional Apoptosis Induced by Oncogenic Ras in Thyroid Cells | 2.5 | 53 | Citations (PDF) |
| 273 | Involvement of Protein Kinase Cε (PKCε) in Thyroid Cell Death | 2.2 | 71 | Citations (PDF) |
| 274 | Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas | 4.0 | 64 | Citations (PDF) |
| 275 | Identification of Rapid Turnover Transcripts Overexpressed in Thyroid Tumors and Thyroid Cancer Cell Lines: Use of a Targeted Differential RNA Display Method to Select for mRNA Subsets | 15.5 | 38 | Citations (PDF) |
| 276 | Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. | 4.1 | 142 | Citations (PDF) |
| 277 | Early treatment of hereditary medullary thyroid carcinoma after attribution of multiple endocrine neoplasia type 2 gene carrier status by screening for ret gene mutations | 1.8 | 81 | Citations (PDF) |
| 278 | Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype. | 4.1 | 56 | Citations (PDF) |
| 279 | Expression of p21 ras protein as a prognostic factor in papillary thyroid cancer | 4.9 | 37 | Citations (PDF) |
| 280 | Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. | 4.1 | 228 | Citations (PDF) |
| 281 | Expression of thyrotropin receptor (TSH-R), thyroglobulin, thyroperoxidase, and calcitonin messenger ribonucleic acids in thyroid carcinomas: evidence of TSH-R gene transcript in medullary histotype | 4.1 | 48 | Citations (PDF) |
| 282 | Detection of thyroid-stimulating antibody using Chinese hamster ovary cells transfected with cloned human thyrotropin receptor. | 4.1 | 84 | Citations (PDF) |
| 283 | Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. | 4.1 | 202 | Citations (PDF) |
| 284 | Medullary Thyroid Cancer: An Immunohistochemical and Humoral Study Using Six Separate Antigens | 0.7 | 87 | Citations (PDF) |
| 285 | Demonstration of the Existence of the Alternatively Spliced Form of Thyroid Peroxidase in Normal Thyroid* | 4.1 | 26 | Citations (PDF) |
| 286 | Studies with Recombinant Autoepitopes of Thyroid Peroxidase: Evidence Suggesting an Epitope Shared Between the Thyroid and the Gastric Parietal Cell | 3.1 | 39 | Citations (PDF) |
| 287 | Somatostatin in medullary thyroid cancer.In vitro andin vivo studies | 4.0 | 47 | Citations (PDF) |
| 288 | Postoperative thyroglobulin and neck ultrasound in the risk re-stratification and decision to perform 131I ablation | 4.1 | 39 | Citations (PDF) |
| 289 | Systemic treatment of advanced, metastatic, medullary thyroid carcinoma 0, , | | 3 | Citations (PDF) |
| 290 | Correlation of Performance Status and Neutrophil-Lymphocyte Ratio with Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Lenvatinib | 4.4 | 41 | Citations (PDF) |
| 291 | Calcitonin receptor expression in medullary thyroid carcinoma | 0.0 | 7 | Citations (PDF) |
| 292 | Prevalence and genetics of “de novo” MEN2 syndromes | 4.1 | 1 | Citations (PDF) |
| 293 | Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma | 4.4 | 1 | Citations (PDF) |
| 294 | Highly-selected sporadic, apparently unifocal cN0 MTC may benefit from unilateral surgery. A proof of concept in a high-volume institution | 1.8 | 0 | Citations (PDF) |
| 295 | Liquid Biopsy-Based
RET
Mutation Profiling to Guide
RET
Inhibitor Treatment in Sporadic Medullary Thyroid Carcinoma May Be Useful in Cases with High Tumor Burden and Progressive Disease | 4.4 | 0 | Citations (PDF) |
